Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

EMTN Programme issue - publication of Final Terms

19th Sep 2023 15:01

RNS Number : 9623M
GlaxoSmithKline Capital PLC
19 September 2023
 

Issued: 19 September 2023, London UK

 

GlaxoSmithKline Capital plc Publication of Final Terms

 

 

The final terms dated 19 September 2023 (the "Final Terms") in respect of the issue by GlaxoSmithKline Capital plc of ¥42,500,000,000 Fixed Rate Notes due 21 September 2028 (the "Notes") is available for viewing.

 

The Notes will be guaranteed by GSK plc and will be issued under the £20,000,000,000 Euro Medium Term Note Programme (the "Programme").

 

A copy of the Final Terms has been submitted to the Financial Conduct Authority's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS). A copy can be viewed at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Company SecretaryGlaxoSmithKline Capital plc980 Great West RoadBrentfordMiddlesexTW8 9GSUnited Kingdom

[email protected]

 

Enquiries:

 

UK Media enquiries:

Tim Foley

+44 (0) 20 8047 5502

(London)

European Analyst/Investor enquiries:

Nick Stone

James Dodwell

+44 7717 618 834

+44 7881 269 066

(London)

(London)

 

 

BASIS ON WHICH YOU MAY ACCESS THE FINAL TERMS AND THE PROSPECTUS (THE "BASE PROSPECTUS") PREPARED IN CONNECTION WITH THE PROGRAMME

Please note that the information contained in the Final Terms and the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms or the Base Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

 

Your right to access this service is conditional upon complying with the above requirements.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company.

 

Registered in England & Wales:

No. 2258699

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFTGPUBABUPWGWB

Related Shares:

Glaxosmsc 5.25%
FTSE 100 Latest
Value8,632.33
Change89.77